What dose should produce weight loss?
1 mg or higher for most patients on Ozempic; Wegovy at 2.4 mg is the FDA-approved weight loss formulation.
How long should it take?
Most patients see measurable loss by week 8-12 at therapeutic doses.
Can you build tolerance?
True tolerance is uncommon; plateau is biological adaptation.
Should I go to a higher dose?
Discuss with your prescriber; dose escalation is often the next step.
Does eating affect results?
Yes substantively; reduced appetite isn't the same as reduced intake.
Does alcohol affect weight loss?
Yes; alcohol calories don't engage satiety mechanisms.
Can sleep affect weight loss?
Yes; sleep deprivation alters ghrelin, leptin, cortisol, and insulin sensitivity.
What if I'm losing inches but not pounds?
Body composition change; muscle gain and fat loss can mask scale change.
When should I see my doctor?
After 12-16 weeks at therapeutic dose without progress, or sooner with side effects or symptoms.
- Why Am I Not Losing Weight on Wegovy? The Six Levers Worth Pulling
- Why Am I Not Losing Weight on Mounjaro? Plateau Patterns and Real Causes
- Not Losing Weight on Ozempic: A Troubleshooting Checklist
- Why Am I Not Losing Weight on Zepbound? Plateau Realities and Course Correction
- Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations
- Why Am I Not Losing Weight on Tirzepatide? Decoding Stalled Progress
Sources
- Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, March 2021 (STEP 1)
- Rubino D et al., "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance," JAMA, April 2021 (STEP 4)
- Ozempic FDA prescribing information
- Wegovy FDA prescribing information
- Tasali E et al., "Effect of Sleep Extension on Objectively Assessed Energy Intake," JAMA Internal Medicine, March 2022
- Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022 (SURMOUNT-1)
- Spiegel K et al., "Brief Communication: Sleep Curtailment Affects Appetite," Annals of Internal Medicine, 2004
- American College of Endocrinology consensus statements on obesity
- National Sleep Foundation guidance on sleep duration
- Centers for Disease Control alcohol use guidelines
- American Thyroid Association screening guidelines
Platform Disclaimer. FormBlends connects patients with licensed prescribers for GLP-1 therapy evaluation and management. This article is educational; it does not replace clinical advice from your prescriber. Individual situations require individual assessment.
Compounded Medication Notice. Compounded semaglutide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. STEP trial data applies to brand Ozempic and Wegovy specifically.
Results Disclaimer. Individual weight outcomes vary significantly. STEP 1 reported a 14.9% mean weight loss at week 68; the distribution included substantial variation. Your result depends on dose, adherence, baseline weight, lifestyle, and individual physiology.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →